NCT01239875 - Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

November 24, 2015

Study Completion Date

July 17, 2019

Conditions

Cutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaAdult Diffuse Mixed Cell LymphomaAdult Diffuse Small Cleaved Cell LymphomaAdult Grade III Lymphomatoid GranulomatosisAdult Immunoblastic Large Cell LymphomaAdult Lymphoblastic LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3 Follicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaSmall Lymphocytic LymphomaSplenic Marginal Zone LymphomaWaldenstrom Macroglobulinemia With Nodal Disease

Interventions

BIOLOGICAL

dendritic cell vaccine therapy

Given intratumorally

PROCEDURE

cryotherapy

Undergo cryoablation

BIOLOGICAL

pneumococcal polyvalent vaccine

Given intramuscularly

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

immunoenzyme technique

Correlative studies

OTHER

immunohistochemistry staining method

Correlative studies

BIOLOGICAL

autologous dendritic cell-tumor fusion vaccine

Given intradermally

Trial Locations (1)

55905

Mayo Clinic, Rochester